David Sehy - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.


Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

David Sehy

Account Manager Western US

After having studied macrophage activation and class II MHC gene regulation, David received an M.Sc. in molecular immunology.  Initially, David studied the effects of the red cell growth factor activin on BFU-E at The Scripps Research Institute. Subsequently, he moved from academia to industry and was involved in start-up stage and early stage biotechnology companies PharMingen, eBioscience, and BioLegend with roles in R&D, QC, Technical Support, and Product Management.  Upon the acquisition of PharMingen by BD Biosciences, David was part of a novel field applications group for multiparameter cell analysis and multiplexed immunoassays, covering western USA.  At Bio-Techne, David was part of the first field sales group supporting cell and gene therapy and GMP products. David’s core interests are antigen-presenting cells, cytokines, immunophenotyping, and assay development. 

Favourite Quotation:  

“The challenge for us as immunologists is to ….develop innovative solutions that do better than nature…. Immunity ranks with the most complex of complex systems, along with neurobiology and climate change.” -P.C. Doherty and S.J. Turner. 

Headshot of David Sehy